Pneomococcal Vaccine Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Immunogenicity and Clinical Efficacy of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Lymphoma Survivors After Treatment With Anti-CD20 Therapy
Condition: Lymphoma Intervention: Biological: PCV20 Sponsor: M.D. Anderson Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
A Clinical Trial to Evaluate the Immunogenicity and Safety of the 23-valent Pneumococcal Polysaccharide Vaccine in Healthy People
Condition: Pneumococcal Disease Interventions: Biological: 23-valent pneumococcal polysaccharide vaccine; Biological: control pneumococcal polysaccharide vaccine Sponsor: Aimei Vacin BioPharm (Zhejiang) Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Immunogenicity and Clinical Efficacy of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Lymphoma Survivors After Treatment With Anti-CD20 Therapy
Condition: Lymphoma Intervention: Biological: PCV20 Sponsor: M.D. Anderson Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
A Clinical Trial to Evaluate the Immunogenicity and Safety of the 23-valent Pneumococcal Polysaccharide Vaccine in Healthy People
Condition: Pneumococcal Disease Interventions: Biological: 23-valent pneumococcal polysaccharide vaccine; Biological: control pneumococcal polysaccharide vaccine Sponsor: Aimei Vacin BioPharm (Zhejiang) Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Immunogenicity and Clinical Efficacy of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Lymphoma Survivors After Treatment With Anti-CD20 Therapy
Condition: Lymphoma Intervention: Biological: PCV20 Sponsor: M.D. Anderson Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
A Clinical Trial to Evaluate the Immunogenicity and Safety of the 23-valent Pneumococcal Polysaccharide Vaccine in Healthy People
Condition: Pneumococcal Disease Interventions: Biological: 23-valent pneumococcal polysaccharide vaccine; Biological: control pneumococcal polysaccharide vaccine Sponsor: Aimei Vacin BioPharm (Zhejiang) Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Immunogenicity and Clinical Efficacy of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Lymphoma Survivors After Treatment With Anti-CD20 Therapy
Condition: Lymphoma Intervention: Biological: PCV20 Sponsor: M.D. Anderson Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
A Clinical Trial to Evaluate the Immunogenicity and Safety of the 23-valent Pneumococcal Polysaccharide Vaccine in Healthy People
Condition: Pneumococcal Disease Interventions: Biological: 23-valent pneumococcal polysaccharide vaccine; Biological: control pneumococcal polysaccharide vaccine Sponsor: Aimei Vacin BioPharm (Zhejiang) Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Immunogenicity and Clinical Efficacy of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Lymphoma Survivors After Treatment With Anti-CD20 Therapy
Condition: Lymphoma Intervention: Biological: PCV20 Sponsor: M.D. Anderson Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
A Clinical Trial to Evaluate the Immunogenicity and Safety of the 23-valent Pneumococcal Polysaccharide Vaccine in Healthy People
Condition: Pneumococcal Disease Interventions: Biological: 23-valent pneumococcal polysaccharide vaccine; Biological: control pneumococcal polysaccharide vaccine Sponsor: Aimei Vacin BioPharm (Zhejiang) Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Immunogenicity and Clinical Efficacy of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Lymphoma Survivors After Treatment With Anti-CD20 Therapy
Condition: Lymphoma Intervention: Biological: PCV20 Sponsor: M.D. Anderson Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years
Conditions: Influenza; Community-acquired Pneumonia; Cardiovascular Events Interventions: Biological: Adjuvanted Quadrivalent Inactivated Influenza Vaccine (aIIV4); Biological: High-Dose Quadrivalent Inactivated Influenza Vaccine (HD-IIV4) Sponsors: Kaiser Permanente; Seqirus Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 8, 2023 Category: Research Source Type: clinical trials
